Furthermore, a recent clinical trial for a CCR5 inhibitor treatment to patients suffering from liver metastasis of colorectal cancer showed its effect on reducing tumor mass with better prognosis, suggesting CCL5–CCR5 axis might also provide a procancer activity22. The gene discussed is CCR5; the disease is colorectal cancer.